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Summary
Many viruses modify cellular processes for their own
benefit. The enterovirus 3A protein inhibits endoplas-
mic reticulum (ER)-to-Golgi transport, a function pre-
viously suggested to be important for viral suppres-
sion of immune responses. Here, we show that
a virus carrying a 3A protein defective in inhibiting
ER-to-Golgi transport is indeed less virulent in mice,
and we unravel the mechanism by which 3A inhibits
this trafficking step. Evidence is provided that 3A in-
hibits the activation of the GTPase ADP-ribosylation
factor 1 (Arf1), which regulates the recruitment of the
COP-I coat complex to membranes. 3A specifically
inhibits the function of GBF1, a guanine nucleotide ex-
change factor for Arf1, by interacting with its N termi-
nus. By specifically interfering with GBF1-mediated
Arf1 activation, 3A may prove a valuable tool in dis-
secting the early steps of the secretory pathway.
Introduction
Enteroviruses (e.g., polioviruses, coxsackieviruses, and
ECHOviruses), members of the family of Picornaviridae,
are important human pathogens that are implicated in
a wide spectrum of both acute and chronic conditions,
including poliomyelitis, meningoencephalitis, pancreati-
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6 These authors contributed equally to this work.tis, and myocarditis. Enteroviruses are nonenveloped,
cytolytic viruses that contain a 7.5 kb single-stranded
RNA genome, which encodes four capsid proteins and
a number of nonstructural proteins. The nonstructural
proteins are involved in viral RNA replication and
account for the virus-induced alterations in host cell
metabolism and structure, which serve to create an en-
vironment that is suitable for efficient viral RNA replica-
tion and/or to suppress antiviral host cell responses.
One of the most prominent morphological alterations
in enterovirus-infected cells is the massive accumula-
tion of membrane structures in the cytoplasm. These re-
arranged membranes, which are the sites at which viral
RNA replication takes place, are most likely derived from
the secretory pathway (Bienz et al., 1994). In addition, an
autophagic mechanism for the formation of these mem-
branes has been described (Suhy et al., 2000; Jackson
et al., 2005). The viral 2BC protein plays an important
role in this membrane rearrangement, possibly in con-
junction with the 3A protein (Cho et al., 1994; Suhy
et al., 2000; Jackson et al., 2005).
Another important modification is the inhibition of in-
tracellular protein transport, which becomes apparent
at 3–4 hr postinfection (Doedens and Kirkegaard,
1995). Ectopic expression of the individual nonstructural
proteins showed that viral proteins 2B (and its precursor
2BC) and 3A were each able to inhibit protein transport
in the absence of infection (Doedens and Kirkegaard,
1995; Wessels et al., 2005). The ability of the 2B(C) pro-
tein to inhibit protein transport is most likely linked to its
membrane rearranging activity and, thereby, to its func-
tion in replication. The ability of 3A to inhibit protein
transport is not required for efficient replication but
may serve to reduce infection-limiting host responses.
Viruses carrying a mutation in 3A that rendered it defec-
tive in inhibiting transport replicated efficiently but
showed a reduced ability to suppress cytokine secretion
and MHC-I-dependent antigen presentation in tissue
culture cells (Deitz et al., 2000; Dodd et al., 2001 Wessels
et al., 2005). Moreover, 3A has been demonstrated to re-
duce sensitivity of cells to TNF-a-induced apoptosis by
eliminating TNF-a receptors from the plasma membrane
(Neznanov et al., 2001). Thus, transport inhibition by 3A
may be of importance for the in vivo infectivity of entero-
viruses by suppressing both innate and adaptive
immune responses as well as the extrinsic apoptotic
pathway. 3A blocks transport at a step between the
endoplasmic reticulum (ER) and the Golgi complex
(Doedens and Kirkegaard, 1995; Doedens et al., 1997;
Wessels et al., 2005), but the mechanism remains to
be elucidated.
Bidirectional transport between the ER and Golgi is
mediated by tubulovesicular transport containers that
depend on two coat complexes, COP-II and COP-I
(Scales et al., 1997; Aridor et al., 1995). The COP-II
coat is recruited to the membrane by the GTPase Sar1
and is involved in membrane deformation and vesicle
formation at ER exit sites (ERES), specialized domains
at the ER where secretory cargo is concentrated (Bar-
lowe et al., 1994). Following budding, the vesicles fuse
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ER-Golgi-intermediate compartment (ERGIC). VTCs are
transported along microtubules to the cis side of the
Golgi complex, where they fuse with Golgi membranes
(Lippincott-Schwartz et al., 1998). The COP-I coat acts
in retrograde transport within the Golgi (Orci et al.,
1997) and from the Golgi and VTCs to the ER (Letourneur
et al., 1994), a pathway that coexists with a COP-I-inde-
pendent retrograde pathway (Girod et al., 1999). COP-I
function is also required for ongoing anterograde trans-
port (Rabouille and Klumperman, 2005). Recruitment of
the COP-I coat requires the membrane association of
ADP-ribosylation factor 1 (Arf1), a small GTPase that cy-
cles between an inactive (GDP bound) cytosolic state
and an active (GTP bound) membrane bound state
(reviewed in Moss and Vaughan, 1998, and Shin and
Nakayama, 2004). Cycling of Arf1 between its GTP and
GDP bound state is catalyzed by guanine nucleotide ex-
change factors (GEFs) and GTPase-activating proteins
(GAPs).
In this study, we show the in vivo relevance of the
transport inhibiting function of 3A in a mouse model,
and we unravel the molecular mechanism by which 3A
protein inhibits ER-to-Golgi transport. Evidence is pre-
sented that 3A inhibits COP-I assembly by interfering
with the function of GBF1, a GEF for Arf1, thereby block-
ing the activation of Arf1.
Results
A Virus Carrying a 3A Protein that Is Unable to Inhibit
Protein Transport Is Less Virulent in Mice
It has been suggested that transport inhibition by 3A is
of importance for the in vivo infectivity of enteroviruses,
but this has not yet been experimentally demonstrated.
Here, we investigated the in vivo relevance of the 3A-
mediated transport inhibition during coxsackievirus B3
(CVB3) infection with a mouse model of CVB3-induced
acute myocarditis (Henke et al., 1995). For this, a mutant
virus was generated carrying a serine insertion at posi-
tion 16 in 3A (the corresponding mutation was previ-
ously shown to disrupt the ability of poliovirus 3A to
inhibit transport, Doedens et al., 1997). This mutation
(3A-ins16S) rendered 3A defective in inhibiting protein
transport, as shown by the inability of 3A-ins16S to in-
hibit secretion of a reporter protein (Figure 1A), but did
not interfere with the function of 3A in virus replication
in tissue culture cells (Figure 1B).
Upon intraperitoneal infection of C57BL/6 mice (4 3
107 TCID50 per mouse), wild-type (wt) CVB3 efficiently
replicated in the pancreas (Figure 1C) from where it dis-
seminated to the heart (Figure 1D), as described earlier
for this virus-induced myocarditis model (Henke et al.,
1995). The mutant virus (CVB3-3AinsS16) showed a re-
duced infectivity; the virus titer in the pancreas was
about 100-fold reduced at 3 days postinfection and
reached its maximum later than wt virus (Figure 1C),
and hardly any virus was detected in the heart
(Figure 1D). In addition, there were clear differences in
histopathological changes induced in the heart; symp-
toms of myocarditis (i.e., myocyte necrosis, fibrotic
alterations, and mononuclear cell infiltration) were ob-
served in mice infected with wt virus but not in those
infected with the mutant virus (Figure 1E). Similar resultswere obtained in BALB/c mice (data not shown). Overall,
these data provide evidence that inhibition of protein
transport by 3A is indeed of physiological importance
for the virulence of the virus.
Effects of 3A on Steady-State Distribution of Early
Secretory Pathway Components
To obtain more insight into the mechanism by which the
3A protein inhibits ER-to-Golgi transport, we examined
protein trafficking and steady-state distribution of early
secretory pathway components in Buffalo green mon-
key (BGM) kidney cells transiently expressing the
CVB3 3A protein. The 3A protein was expressed as
a myc-tagged protein or GFP fusion protein (Wessels
et al., 2005), both of which were as efficient in inhibiting
protein transport as untagged 3A (data not shown).
Protein trafficking was examined with the temperature-
sensitive ts045 mutant of the vesicular stomatitis virus
glycoprotein (VSV-G) and soluble GFP targeted to the
lumen of the ER (lum-GFP), well-known membrane
bound and soluble markers for secretory pathway trans-
port, respectively. In 3A-expressing cells, both VSV-G
(Figure 2A) and lum-GFP (data not shown) accumulated
in the ER and a punctate post-ER compartment, colocal-
izing with 3A. The punctate 3A-containing structures
overlapped with the COP-II-coated ERES, as identified
with antibodies against Sec24 (Figure 2B) and Sec13
(data not shown). Since both Sec24 and Sec13 are re-
cruited to the membrane as heteromultimers (Sec24/
Sec23 and Sec13/Sec31, respectively) (Matsuoka
et al., 1998), this finding suggests that the COP-II coat
is intact. Strikingly, ERES morphology in 3A-expressing
cells was significantly altered. Control cells (shown in
Figure 2B and Figure S1 in the Supplemental Data avail-
able with this article online) typically contain many ERES
that are distributed stochastically along the ER, with the
highest density in the juxtanuclear region. In 3A-ex-
pressing cells, most ERES were found in the cell periph-
ery and appeared enlarged, while their total number was
reduced, suggesting clustering of individual ERES
(Figure 2B). VTC and Golgi morphology were also dras-
tically altered in 3A-expressing cells. In control cells,
ERGIC53, a marker for VTC, can be typically found in
peripheral punctate structures close to the ERES and
in the juxtanuclear region close to the cis-Golgi (Ward
et al., 2001) (Figure 2C). In 3A-expressing cells, however,
ERGIC53 localized almost exclusively to 3A-containing
peripheral punctate structures (Figure 2C). GM130,
a Golgi matrix protein, was also redistributed to these
peripheral punctate structures (Figure 2D), whereas gal-
actosyltransferase (GalT), a Golgi resident enzyme, was
found both in the ER and the punctate structures
(Figure 2E). Similar results were obtained in several other
cell lines, indicating that the effects of 3A on the early se-
cretory pathway are not cell-type specific. The effects of
3A closely resembled those of Arf1-T31N, a dominant
negative mutant of Arf1 (Dascher and Balch, 1994), and
of a 2 hr treatment with Brefeldin A (BFA), a well-known
inhibitor of Arf1 activation, both of which cause redistri-
bution of VTC and Golgi proteins into the ER, ERES, and
arrested VTCs (Ward et al., 2001) (see Figure S1).
Next, we examined the effects of 3A on mediators of
the COP-I machinery. Recruitment of the COP-I coat re-
quires the activation of Arf1. In control cells, COP-I and
Enterovirus Protein 3A Blocks Arf1 Activation
193Figure 1. Coxsackievirus Carrying a 3A Mu-
tant that Is Unable to Inhibit Protein Transport
Is Less Virulent in Mice
(A) Analysis of A1PI secretion in cells ex-
pressing no 3A, GFP-3A wt, or a GFP-3A mu-
tant containing a serine insertion at position
16 (3A-ins16S). Average secretion (means 6
SEM) of three independent experiments is
shown. A1PI secretion was calculated as
the percentage of A1PI secretion in control
cells, which was normalized to 100%.
(B) Single-cycle growth curves of wt virus and
virus containing mutation 3A-ins16S at 37ºC.
Cells were infected at a multiplicity of infec-
tion of ten, and the virus titers were deter-
mined at various times postinfection (p.i.) by
endpoint titration and expressed in 50% tis-
sue culture infective doses (TCID50) per ml.
(C and D) Replication of wt virus and 3A-
ins16S mutant virus in C57BL/6 mice (6–8
weeks old, male). The amount of infectious
virus (TCID50 per 50 ml) in pancreas (C) and
heart (D) was determined by endpoint titra-
tion at 3, 5, or 7 days p.i. Animal groups con-
sisted of three to five mice, and experiments
were repeated three times. The mean 6 SEM
is shown.
(E) Histological analysis. The histological
grades of heart lesions were scored as de-
scribed earlier (Merkle et al., 2002). The myo-
carditis index is the mean of the values for
cellular infiltration, necrosis, and fibrosis. An-
imal groups consisted of ten mice, and the
mean 6 SEM is shown.Arf1 localize at VTC and Golgi membranes. In 3A-ex-
pressing cells, however, neither COP-I nor Arf1 were as-
sociated with membranes (Figures 2F and 2G), suggest-
ing that Arf1 resides in its inactive, cytosolic state. GBF1
and ArfGAP1, which have been implicated as a GEF and
GAP for Arf1 in ER-to-Golgi transport, respectively, nor-
mally localize at VTC and Golgi membranes (Cukierman
et al., 1995; Zhao et al., 2002; Niu et al., 2005). Expres-
sion of 3A resulted in redistribution of GBF1 from the
Golgi region to a dispersed localization throughout the
cell (Figure 2H). ArfGAP1 was redistributed to the pe-
ripheral punctate structures (Figure 2I). We also studied
the effects of 3A on the TGN and the TGN-associated
large Arf GEFs BIG1 and BIG2 (Zhao et al., 2002). Ex-
pression of 3A had a profound effect on the structure
of the TGN, causing TGN46 to redistribute from its nor-
mal compact localization to a dispersed localization
(Figure 2J). Expression of 3A also resulted in a redistri-
bution of BIG1 and BIG2 to a dispersed localization
throughout the cell (Figures 2K and 2L). Again, similar
effects were observed in cells treated with BFA or
expressing Arf1-T31N (Figure S1).
Ultrastructural Analysis and Dynamics of Early
Secretory Pathway Components
in 3A-Expressing Cells
From the immunofluorescence data, it can be concluded
that 3A is localized on COP-I-depleted membrane
structures that contain markers for ERES, VTCs, andGolgi. To investigate the structural organization and
molecular composition of these membranes at the ultra-
structural level, we performed immuno-electron micros-
copy (EM) studies with antibodies against Sec23 and
ERGIC53. In control HeLa cells, Sec23 was found on
budding profiles on the ER as well as on associated
vesicular-tubular membranes (Figure 3A), whereas
ERGIC53 was found in the cis-most Golgi cisterna
(Figure 3C) and VTC membranes at the cis side of the
Golgi complex (Figure 3D). 3A expression resulted in
a massive accumulation of 3A-positive vesicular and tu-
bular membranes facing the ERES, which were partially
positive for Sec23 (Figure 3B) as well as ERGIC53 (Fig-
ures 3E). Sometimes, the 3A-positive budding profiles
were seen connected with the ER in the plane of the sec-
tion (Figure S2).
We also studied the dynamics of the COP-II coat and
ERGIC53. Fluorescence recovery after photobleaching
(FRAP) experiments on cells coexpressing 3A and
Sec24-YFP or p58-ERGIC-YFP, a rat ERGIC53 homolog,
showed that the COP-II coat still cycled on and off mem-
branes and that p58-ERGIC shuttled between the ER
and the above described membrane structures (Fig-
ure 4). However, the dynamic behavior of these proteins
was somewhat affected; the halftime of fluorescence
recovery of Sec24-YFP was increased (17.0 6 1.6 s
versus 8.4 6 0.6 s in control cells) (Figure 4A), whereas
there was little effect on the halftime of fluorescence re-
covery of p58-ERGIC-YFP, but its mobile fraction was
Developmental Cell
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(A) Cells transfected with VSVG-GFP and 3A-myc were incubated at 40ºC for 16 hr to accumulate VSV-G in the ER and subsequently shifted to
32ºC for 2 hr. 3A was stained with an antibody against myc.
(B–L) GFP-3A-expressing cells (16 hr after transfection) stained with antibodies against Sec24 (B), ERGIC53 (C), GM130 (D), a/g-COP (F), Arf1 (G),
GBF1 (H), ArfGAP1 (I), TGN46 (J), BIG1 (K), and BIG2 (L). One or more control cells are shown in all figures. (E) Cells coexpressing GalT-GFP and
3A-myc (16 hr after transfection). Bars represent 10 mm.increased (Figure 4B). Similar features were observed in
cells treated with BFA or expressing Arf1-T31N (Fig-
ure 4). The reason for the observed alterations in dynam-
ics of Sec24 and p58-ERGIC are yet unknown. Recently,
a linkage was suggested between COP-II dynamics and
the availability of secretory cargo (Forster et al., 2006).
Reduced amounts of cargo were shown to reduce the
halftime recovery of Sec23. Thus, the increase in the
halftime recovery of Sec24 that we observed in the pres-
ence of 3A, BFA, or Arf1-T31N may be due to the accu-
mulation of transport competent cargo in the ER.
3A Blocks Activation of Arf1 by Inhibiting an Arf GEF
To study the activation state of Arf1 in 3A-expressing
cells, we performed pull-down experiments with a
GST-GGA3-GAT domain fusion protein (Shinotsukaet al., 2002). The GAT domain of GGA3, an effector of
Arf1, binds specifically and with high affinity to Arf1-
GTP and provides a tool to monitor the amount of
Arf1-GTP in cell lysates (Boman, 2001). To ensure that
we only measured the Arf1 activation state in 3A-
expressing cells, we made use of a single construct
expressing both 3A (from a CMV promoter) and GFP-
tagged Arf1 (from a SV40 promoter). Low level expres-
sion of Arf1-GFP from the SV40 promoter (of which the
expression level in BGM cells is considerably less than
from the CMV promoter; Wessels et al., 2005) did not in-
terfere with the function of 3A, as shown by dissociation
of COP-I and Arf1-GFP from membranes (Figure S3). In
3A-expressing cells, the amount of Arf1-GTP was
greatly reduced compared to control cells (Figure 5A),
indicating that 3A blocks activation of Arf1. In cells
Enterovirus Protein 3A Blocks Arf1 Activation
195Figure 3. Immuno-Electron Microscopy of
Control and 3A-Expressing HeLa Cells
(A) In control cells, COP-II (Sec23, 15 nm gold)
was found on ER budding profiles (arrow) and
associated vesicles. The asterisk indicates
COP-II-negative VTC membranes.
(B) 3A expression (10 nm gold) leads to an ac-
cumulation of ER-associated vesicles and tu-
bules that are sometimes also positive for
COP-II (15 nm gold, arrowhead). The asterisk
marks the VTC area.
(C and D) ERGIC53 (15 nm gold) normally lo-
calizes to the cis-Golgi cisterna (arrowhead
in [C]) and Golgi-associated VTC membranes
(D).
(E) In 3A (10 nm gold)-expressing cells,
ERGIC53 (15 nm gold) is found on a portion
of the 3A-induced membrane clusters. The
asterisk marks the VTC area. Images were
taken from cells fixed at 32 hr after transfec-
tion. ER, endoplasmic reticulum; G, Golgi;
M, mitochondrion; E, endosome; NE, nuclear
envelope; N, nucleus. Bars represent 200 nm.expressing the defective 3A-ins16S mutant, normal
Arf1-GTP levels were observed (Figure 5A) and both
Arf1 and COP-I were observed at intact VTC and Golgi
membranes (data not shown). These data strongly sug-
gest that 3A inhibits ER-to-Golgi transport by blocking
Arf1 activation.
We also examined the effect of 3A on the diffusion be-
havior of Arf1-GFP by fluorescence correlation spec-
troscopy (FCS), a technique that measures the diffusion
of fluorescent proteins in living cells. The results show
that Arf1 behaves as a cytosolic, freely diffusing protein,
lending further support to the idea that Arf1 is persis-
tently inactive in 3A-expressing cells (Figure S3).
BFA blocks Arf1 activation by inhibiting the activity of
the high-molecular-weight Arf GEFs GBF1, BIG1, and
BIG2 (Moss and Vaughan, 1998; Peyroche et al., 1999;
Niu et al., 2005). We tested whether 3A also blocks
Arf1 activation by inhibiting an Arf GEF activity by in vitro
GEF assays (Figure 5B and Figure S4). Recombinant
myristoylated Arf1 and rat liver Golgi membranes (as
a source of GEFs and membranes) were incubated in
the presence of 35S-GTPgS together with or without re-
combinant 3A, after which the amount of membrane
bound label was determined. In these experiments, the
N-terminal 60 aa of wt 3A and the defective 3A-ins16S
mutant were tested (i.e., the cytosolic domain located
upstream of the C-terminal membrane anchor of 3A;
Figure S5). Addition of wt 3A, but not of 3A-ins16S,resulted in a strong reduction of Arf GEF activity
(Figure 5B). Together, these data suggest that 3A in-
hibits Arf1 activation by inhibiting an Arf GEF activity.
3A Interacts with GBF1 and Arf1-GDP
To identify the Arf GEF that is inhibited by 3A, we tested
possible interactions between the N-terminal 60 aa and
the three-abovementioned high-molecular-weight GEFs
by yeast two hybrid. For each of the three GEFs, three
portions covering the complete protein were tested
(the N-terminal part upstream of the catalytic Sec7 do-
main, the Sec7 domain itself, and the C-terminal part
downstream of the Sec7 domain; Figure 5C). A strong in-
teraction was observed between 3A and the N-terminal
portion of GBF1 (Figure 5D). No interactions were ob-
served with any other of the tested GEF domains or
with Arf1 (neither with wt Arf1, the inactive Arf1-T31N
mutant, nor the active Arf1-Q71L mutant). The interac-
tion of 3A with GBF1 was confirmed by an in vitro
GST-pull-down approach from both mouse brain lysate
and isolated rat liver Golgi membranes (Figure 5E and
data not shown) and by coimmunoprecipitation experi-
ments (Figure 5F). In these experiments, Arf1 was found
to be associated with 3A (Figures 5E and 5F). Since
GBF1 binds with high affinity to Arf1-GDP, we reasoned
that the interaction between 3A and Arf1 was mediated
by GBF1. Consistent with this idea, more 3A was copre-
cipitated from cells expressing the inactive (GDP bound)
Developmental Cell
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ERGIC-YFP in 3A-Expressing Cells
(A and B) FRAP traces showing the relative
fluorescence of cells stably expressing
Sec24-YFP (A) or p58-ERGIC-YFP (B), either
alone (control cells), coexpressing CFP-3A
or Arf1-T31N-CFP, or treated with BFA. The
traces in all graphs show the average recov-
ery and SEMs (n R 9 cells, from at least two
independent experiments). The fluorescence
intensity before bleaching was normalized to
1, and the fluorescence intensity directly after
the bleach to 0. The fluorescence intensity
was corrected for bleaching of the cell during
imaging and background fluorescence.
Values for the halftime of fluorescence recov-
ery are calculated from the traces depicted in
(A) and (B).Arf1-T31N mutant than from cells expressing the active
(GTP bound) Arf1-Q71L mutant (Figure 5G). Further evi-
dence was obtained by using an in vitro approach with
recombinant Arf1-T31N and Arf1-Q71L, coupled to col-
umns and saturated with GDP or GTP, respectively,
which showed that upon loading of a 3A-containing
cell lysate, 3A was predominantly retained on the Arf1-
T31N column (Figure 5H).
Overexpression of GBF1 or Arf1 Suppresses
the Effects of 3A
The data described above strongly suggest that 3A in-
terferes with Arf1-dependent COP-I assembly by inhibit-
ing the function of GBF1, which is also one of the targets
of BFA. Overexpression of either Arf1-Q71L or GBF1 has
been described to protect against the effects of BFA
(Claude et al., 1999; Niu et al., 2005; Alvarez et al.,
2003; Teal et al., 1994). We investigated whether overex-
pression of Arf1 and GBF1 could counteract the effects
of 3A. To this end, Arf1-YFP or YFP-GBF1 were ex-
pressed to high levels from CMV promoters together
with 3A. Overexpression of both Arf1 and GBF1 strongly
suppressed 3A function, as shown by the reduced ability
of 3A to cause COP-I dissociation (Figure 6B). Both Arf1
and GBF1 colocalized with 3A to dispersed membrane
structures (Figure 6A), indicating partial rescue, or, oc-
casionally, to intact Golgi structures (data not shown).
Further evidence that overexpression of GBF1 sup-
presses the effects of 3A was obtained by GGA pull-
down (Figure 6C), which showed that GBF1 overexpres-
sion reversed the ability of 3A to block Arf1 activation,
resulting in normal Arf-GTP levels. No such effect was
seen upon overexpression of BIG2.
3A Stabilizes GBF1 on Membranes
Recently, it was reported that GBF1 under physiological
conditions continuously cycles on and off membranes,
and that both Arf1-T31N and BFA stabilize an intermedi-
ate complex of GBF1 and Arf1-GDP on membranes (Niuet al., 2005; Szul et al., 2005). We investigated the effects
of 3A on YFP-GBF1 dynamics. Upon coexpressing YFP-
GBF1 and CFP-3A, GBF1 was mostly found on dis-
persed membranes (see Figure 6A). FRAP experiments
showed that the YFP-GBF1 fluorescence recovered
very slowly and only to a limited amount in 3A-express-
ing cells compared to control cells, indicating that GBF1
is bound much more stably on membranes in cells ex-
pressing 3A (Figure 7A). Analysis of the Arf-YFP dynam-
ics, which similarly localized on dispersed membrane
structures (see Figure 6A), showed that the halftime of
fluorescence recovery of Arf1-YFP in 3A-expressing
cells (4.26 0.7 s) was significantly decreased compared
to control cells (23.26 1.8 s) (Figure 7B). The 3A-ins16S
mutant that was unable to block activation of Arf1 was
considerably compromised in its ability to trap GBF1
on membranes and had only a minor effect on the cy-
cling of Arf1 (Figures 7A and 7B). These results indicate
that 3A stabilizes GBF1 on membranes in a manner sim-
ilar to BFA and Arf-T31N.
Discussion
Most viruses have developed mechanisms to counter-
act infection-limiting host cell responses. Enteroviruses
are nonenveloped, cytolytic RNA viruses that do not rely
on an intact secretory pathway to release their progeny.
Instead, these viruses induce a general inhibition of se-
cretory pathway transport, most likely to reduce cyto-
kine secretion and MHC-I exposure. The enterovirus
3A protein, a small membrane protein with multiple func-
tions in the viral life cycle, has been suggested to play an
important role in this inhibition by blocking ER-to-Golgi
transport. Here, we showed the physiological relevance
of this function in a mouse model of coxsackievirus in-
fection. We showed that a coxsackievirus carrying a mu-
tation in 3A that rendered it unable to inhibit ER-to-Golgi
transport was less virulent in mice, as indicated by re-
duced virus titers and tissue damage in the target
Enterovirus Protein 3A Blocks Arf1 Activation
197Figure 5. 3A Blocks Arf1 Activation by Interacting with GBF1 and
Arf1-GDP
(A) Arf1-GTP pull-down assay. COS7 cells were transfected with
pCMS-Arf1-GFP, pC-3A-myc-S-Arf1-GFP, or pC-3A-ins16S-myc-
S-Arf1-GFP. The upper panel shows the total amount of Arf1-GFP
in cells, the lower panel shows the amount of GTP bound Arf1-GFP.
(B) In vitro Arf1 GEF assay. Recombinant myristoylated Arf1 and rat
liver Golgi membranes were incubated in the presence of 35S-
GTPgS. The amount of membrane bound label in the absence of
3A (23A) was normalized to 100% and represents the Arf GEF activ-
ity. Recombinant 3A(1–60) proteins (+3A or +3A-ins16S) were added
at a concentration of 1 mM. The average values of two independent
experiments are shown.
(C) Schematic representation of 3A and the high-molecular weight
Arf GEFs. HD, hydrophobic domain (aa 61–82); N, N-terminal part
of GEFs (BIG1, aa 1–708; BIG2, aa 1–653; GBF1, aa 1–709); Sec7,
Sec7 domain of GEFs (BIG1, aa 709–892; BIG2, aa 654–837; GBF1,
aa 710–895); C, C-terminal part of GEFs (BIG1, aa 893–1850; BIG2,
aa 838–1786; GBF1, aa 896–1856).
(D) Yeast two-hybrid analysis shows that the N-terminal 60 aa of 3A
specifically interact with the N-terminal part of GBF1. Left panel
shows growth of yeast on leucine- and tryptophane-deficient me-
dium; middle panel shows growth on histidine-deficient medium;
right panel shows growth on adenine-deficient medium. Interactions
between binding partners result in white colonies on the leu, trp-de-
ficient medium and in growth on his- and ade-deficient media.organs. Moreover, we have unraveled the molecular
mechanism by which 3A inhibits ER-to-Golgi transport.
Evidence is presented that 3A interferes with COP-I
assembly by blocking the activation of Arf1.
Inhibition of COP-I assembly by 3A resulted in disas-
sembly of VTC and Golgi structures and the accumula-
tion of membrane structures at or close to the ERES.
This inhibition was due to impaired Arf1 activation, as
shown by reduced amounts of Arf1 on the membranes
and reduced Arf1-GTP levels. Inhibition of Arf1 activa-
tion may be caused either by inhibition of GEF activity
or, alternatively, by stimulation of GAP activity. Several
results demonstrate that 3A interferes with Arf1 activa-
tion by specifically inhibiting the function of GBF1,
a GEF that has been shown to catalyze nucleotide ex-
change on Arf1 in the ER-Golgi system: (1) two-hybrid
studies as well as GST-pull-down and coimmunopreci-
pitation experiments showed an interaction with GBF1,
(2) the inhibition of Arf1 activation by 3A could be over-
come by overexpression of GBF1, and (3) FRAP experi-
ments showed that GBF1, which normally cycles
between membranes and the cytosol, was trapped on
membranes by 3A. Conversely, no interactions were ob-
served between 3A and ArfGAP1 in pull-down or coim-
munoprecipitation experiments (data not shown). More-
over, recombinant purified 3A had no effect on ArfGAP1
activity in vitro (B. Antonny, personal communication),
whereas at the same concentration, we showed that it
inhibited an Arf GEF activity in vitro. Together, these
data indicate that 3A inhibits GBF1 activity rather than
that it stimulates ArfGAP1 activity. In addition to GBF1,
Arf1 was found to be associated with 3A in pull-down
and coimmunoprecipitation experiments. Additional
coimmunoprecipitation experiments showed that it
was the inactive form of Arf1 (i.e., Arf1-GDP) that was
pulled down along with 3A. No interaction between
Arf1 and 3A was found in the yeast two-hybrid assay. Al-
though this latter finding does not necessarily exclude
a direct interaction, these data strongly suggest that
3A interacts indirectly with Arf1 through GBF1, which
binds with high affinity to Arf1-GDP, but not Arf1-GTP.
Together, our data support a model in which 3A inhibits
ER-to-Golgi transport by stabilizing an intermediate
GBF1-Arf1-GDP complex on membranes in a conforma-
tion that cannot proceed to nucleotide exchange.
The amount of Arf1 present in cells largely exceeds
that of GBF1. Therefore, almost all GBF1, but only a mi-
nor fraction of Arf1, will be trapped in the abortive 3A-
GBF1-Arf1-GDP complex. A similar situation has been
demonstrated for BFA treatment of cells, which stabi-
lizes GBF1 and a minor fraction of Arf1 on membranes
(Niu et al., 2005). In cells expressing 3A, it is this large,
cytosolic Arf1 population that contributes most to our
(E) The N-terminal 60 aa of 3A pull-down GBF1 and Arf1 from mouse
brain lysates.
(F) Co-IP experiments. 3A-myc is specifically coprecipitated from
cells cotransfected with YFP-GBF1 or Arf1-GFP.
(G) Co-IP experiments with the dominant-negative (T31N) and dom-
inant-active (Q71L) mutants of Arf1 show that 3A preferentially inter-
acts with Arf1 in its inactive, GDP bound form (Arf1-T31N).
(H) 3A in CVB3-infected BGM cell lysates preferentially binds to col-
umns containing GDP-saturated, recombinant Arf1-T31N. WB,
Western blot; IP, immunoprecipitation.
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198steady-state studies, explaining the lack of clear colo-
calization between 3A and Arf1. If 3A stabilizes an abor-
tive GBF1-Arf1-GDP complex on membranes, why
then do we find an increased cycling speed of Arf1? Re-
cently, an increased cycling speed was observed for an
Arf1 mutant that was targeted to the TGN, presumably
because its activity was now controlled by trans-Golgi
GEFs (BIG1 and BIG2) and GAPs (Honda et al., 2005).
The dispersed membrane structures to which Arf1 was
redistributed in cells overexpressing 3A and Arf1 not
only contained GBF1 but also BIG1 and BIG2 (data not
shown). Thus, a possible explanation for the increased
Arf1 cycling speed in 3A-expressing cells is that Arf1 is
now exclusively regulated by other GEFs than GBF1.
The effects of 3A on both the steady-state distribution
and the dynamic behavior of early secretory pathway
proteins closely resembled those of BFA. However, the
molecular mechanisms of BFA and 3A are different.
Figure 6. Overexpression of GBF1 or Arf1 Suppresses the Effects of
3A
(A) BGM cells transiently cotransfected with 3A-myc and GFP, Arf1-
GFP, YFP-GBF1, or GM130-GFP for 16 hr were stained with an anti-
body against COP-I. Bars represent 10 mm.
(B) Percentage of 3A-myc and GFP, Arf1-GFP, YFP-GBF1, or
GM130-GFP coexpressing cells, in which COP-I is dissociated
from membranes. Calculations were made from at least two inde-
pendent experiments (of which a typical example is shown in [A]).
In each experiment, at least 100 cells were analyzed.
(C) Arf1-GTP pull-down assay. COS7 cells were transfected with
pCMS-Arf1-GFP or pC-3A-myc-S-Arf1-GFP, either alone or in com-
bination of with YFP-GBF1 or HA-BIG2. The upper panel shows the
total amount of Arf1-GFP in cells, and the lower panel shows the
amount of GTP bound Arf1-GFP.BFA interferes with the activity of all large multidomain
Arf GEFs (i.e., GBF1, BIG1, and BIG2) by binding to the
interface of their catalytic Sec7 domains and Arf1-GDP
(Peyroche et al., 1999; Renault et al., 2003; Mossessova,
et al., 2003). Conversely, overexpression of these pro-
teins can counteract BFA-induced blockage of Arf1 ac-
tivation (Claude et al., 1999; Shinotsuka et al., 2002; E.
Smirnova and C.L.J., unpublished data). In contrast,
3A seems to specifically interfere with the function of
GBF1. 3A specifically binds GBF1, but not BIG1 and
BIG2, and only overexpression of GBF1 restored Arf1-
GTP levels in 3A-expressing cells. Moreover, 3A binds
to the N terminus of GBF1 rather than to its catalytic
Sec7 domain. In line with the idea that 3A does not
directly target the Sec7 domain, 3A was found to be
unable to inhibit nucleotide exchange on Arf1 by the
Sec7 domain of BIG1 in vitro (J. Cherfils, personal com-
munication) (in this experiment BIG1 Sec7 was used be-
cause all attempts to produce active recombinant GBF1
Sec7 have been unsuccessful). Thus, 3A specifically
inhibits GBF1-mediated Arf1 exchange through a mech-
anism that differs from that of BFA.
Enteroviruses induce a dramatic rearrangement of se-
cretory pathway membranes. The 2BC protein triggers
a massive accumulation of membrane structures at
Figure 7. Dynamics of GBF1 and Arf1 in 3A-Expressing Cells
(A and B) FRAP traces of cells expressing YFP-GBF1 (A) or Arf1-YFP
(B), either alone (control cells) or together with CFP-3A or CFP-3A-
ins16S. The traces in the graphs show the average recovery and
SEMs (n R 10 cells, from at least two independent experiments).
The fluorescence intensity was calculated as described in Figure 4.
(C) Inset of (B), showing traces of the first 40 s after bleach.
(D) Halftime of fluorescence recovery values of Arf1-YFP alone, to-
gether with CFP-3A or CFP-3A-insS16, as calculated from the traces
in (B).
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199which viral genome replication takes place. The function
of 3A is not required for this latter modification since vi-
ruses carrying a 3A protein defective in inhibiting ER-to-
Golgi transport replicated efficiently in tissue culture
cells (Doedens et al., 1997; Wessels et al., 2005). Entero-
virus genome replication is completely abolished in the
presence of BFA when added to cells immediately after
infection (Maynell et al., 1992). It may therefore seem re-
markable that enteroviruses produce a protein that
causes BFA-like effects. However, the inhibition of pro-
tein transport in infected cells occurs at a late stage in
infection (at 4–5 hr postinfection), a time point at which
the membrane rearrangements required for initiation of
viral genome replication have already taken place. Ac-
cordingly, virus replication is not inhibited when BFA is
added at late stages in infection (Maynell et al., 1992).
Recently, it was demonstrated that expression of po-
liovirus 3A results in increased membrane association of
Arf1 in HeLa cell lysates (Belov et al., 2005). The reason
why these authors find more Arf1 on membranes upon
expression of 3A in vitro, whereas we find a dissociation
of the majority of the Arf1 population in vivo, is yet un-
known. Notwithstanding this difference, their results
also point to a regulatory role of 3A in Arf1 function. In
addition, these authors showed that also the viral 3CD
protein can increase the membrane association of Arf1
and that Arf1 is redistributed to the membranes where
the viral replication proteins localize (Belov et al.,
2005). Together, the data suggest that early in infection,
active Arf1 is required for the accumulation of the mem-
branes at which viral RNA replication takes place,
whereas late in infection, the function of Arf1 may be in-
hibited to evade antiviral host cell responses. More re-
search is required to establish the relative contributions
and importance of the Arf1-related membrane alter-
ations induced by 3A and 3CD in infected cells.
In another study, it was proposed that poliovirus 3A
inhibits transport by binding and inactivating Lis1,
a component of the dynein/dynactin motor complex
(Kondratova et al., 2005). Given the observation that
Lis2/2 MEFs contain COP-I on their membranes (Sasaki
et al., 2005), it seems unlikely that this activity is involved
in the mechanism by which 3A inhibits Arf1-dependent
COP-I assembly. The activity proposed by Kondratova
et al. most likely occurs downstream of the mechanism
that we described here and may constitute an additional
function of 3A to suppress protein transport.
In conclusion, we have shown that the enterovirus 3A
protein inhibits ER-to-Golgi transport by stabilizing the
Arf GEF GBF1 on membranes and blocking its capacity
to activate Arf1. To our knowledge, the 3A protein is the
first viral protein that is recognized to interfere with Arf1
activation and may prove to be a valuable tool in future
research on the early steps of the secretory pathway.
Experimental Procedures
Cells, Antibodies, and Reagents
Experiments were performed with BGM cells, unless stated other-
wise. The coxsackievirus that was used in this study is a recombi-
nant virus that was derived from plasmid p53CB3/T7, which con-
tains a full-length and infectious cDNA of coxsackievirus B3
(CVB3, strain Nancy) behind a T7 promoter (Wessels et al., 2005).
The 3A-ins16S mutant virus was generated by oligonucleotide-
directed, in vitro mutagenesis as described (Wessels et al., 2005).The following antibodies were used: rabbit polyclonal antibodies
against the first 60 aa of CVB3 protein 3A (raised against recombi-
nant MBP-3A[1–60]), Arf1 (B. Helms, Biochemie-Zentrum Heidel-
berg, Germany), ArfGAP1 (M. Roth, University of Texas Southwest-
ern Medical Center at Dallas), BIG1 and BIG2 (M. Vaughan and J.
Moss, NIH, Bethesda, MD), a/g-COP (K. Frey, Biochemie-Zentrum
Heidelberg, Germany), GFP (raised against recombinant GST-
GFP), the myc-epitope (ABR), Sec13 (B.-L. Tang, National University
of Singapore), Sec23 (ABR, Affinity Bioreagents, Inc.), Sec24 (J.-P.
Paccaud, University of Geneva, Switzerland), TGN46 (Serotec, Ox-
ford, UK), mouse monoclonal antibodies against ERGIC53 (J. Fran-
sen, University of Nijmegen, The Netherlands/H.P. Hauri, Biocenter
Basel, Switzerland), GBF1 (BD Bioscience), GM130 (BD), the myc-
epitope (Sigma), and anti-rabbit and anti-mouse antibodies conju-
gated with Alexa Fluor 594 and Alexa Fluor 488 (Molecular Probes,
The Netherlands). Myristoylated Arf1 was kindly provided by S. Paris
and B. Antonny. Brefeldin A was obtained from Sigma.
Constructs
The following plasmids were kind gifts: pVSVG-GFP (P. Keller and K.
Simons, Max Planck Institute of Molecular Biology and Genetics,
Dresden, Germany); pArf1-GFP, pArf1-Q71L-GFP, and pArf1-
T31N-GFP (G. Romero, University of Pittsburgh); p58-ERGIC-YFP
(J. Lippincott-Schwarz, NIH, Bethesda, MD); pGM130-GFP (F.
Barr, Imperial Cancer Research Fund, London, UK). pYFP-GBF1
(Niu et al. 2005), p3A-myc, and pGFP-3A (Wessels et al., 2005)
were described previously. pC-3A-myc-S-Arf1-GFP and pC-A1PI-
YFP-S-GFP-3A were derived from pCMS-EGFP (Clontech), a plas-
mid that contains both a CMV (C) and a SV40 (S) promoter.
A1PI Secretion Assay
This method was performed as described (Wessels et al., 2005).
Single-Cycle Growth Curve
This method was performed as described (Wessels et al., 2005).
Mouse Experiments
Mouse experiments were performed as described (Henke et al.,
1995). Histological analyses were performed as described in Merkle
et al. (2002). All animal procedures were officially approved in accor-
dance with the German Animal Protection Law.
Immunofluorescence and Immuno-Electron Microscopy
These techniques were performed as described (Wessels et al.,
2005; Slot et al., 1991).
FRAP Experiments
Live cell confocal microscopy was performed on a Zeiss
LSM510Meta confocal microscope (Carl Zeiss GmbH, Jena, Ger-
many) equipped with a temperature-controlled stage and CO2 incu-
bator (type S). FRAP measurements were made from movies that
were taken at 37ºC at a rate of one frame per s (Sec24, GBF1, and
Arf1) or one frame per 10 s (p58-ERGIC) with a 633, 1.4 NA objective
and pinhole settings such that <2 mm optical slices were imaged. To
study the effects of CFP-3A and Arf1-T31N-CFP on protein dynam-
ics, cells were selected on the basis of coexpression. FRAP imaging
was performed with the 514 nm argon line with low laser power con-
ditions (40% power, 0.1% transmission) in order to prevent photo-
bleaching during monitoring. Regions of interest (ROI) were selec-
tively photobleached with the 514 nm line at 100% transmission,
the number of iterations ranging from 25–70 s in order to accomplish
aw50% reduction of the initial ROI intensity. The p58-ERGIC-YFP-
expressing cells were incubated on ice for 30 min and treated with
1 mg/ml nocodazole before imaging to prevent microtubule-depen-
dent motion of pre-Golgi intermediates (Ward et al., 2001). Where
indicated, cells were treated with BFA (5 mg/ml) for 30 min before
imaging.
Arf1-GTP Pull-Down Assay
To assess the amount of activated Arf1-GTP in cells, we performed
a GGA pull-down assay as described (Niu et al., 2005). Briefly, COS7
cells were transfected with a pCMS vector expressing Arf1-GFP
alone or expressing Arf1-GFP and 3A together, either alone or co-
transfected with plasmid expressing YFP-GBF1 or HA-BIG2, and in-
cubated for 20 hr. Cell lysates were prepared and incubated for 1 hr
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200at 4ºC with glutathione-Sepharose beads prebound with a GST-
GGA3-VHS-GAT domain fusion protein (Shinotsuka et al., 2002).
Bound proteins were eluted from beads and subjected to Western
analysis. Both YFP-GBF1 and HA-BIG2 were efficiently expressed
as detected by Western analysis (data not shown).
In Vitro Arf GEF Activity Assays
This assay was performed as described in Donaldson et al. (1992)
with minor modifications. Incubations were carried out in 50 ml reac-
tion mixtures containing 25 mM HEPES-KOH (pH 7.0), 25 mM KCl,
2.5 mM MgCl2, 0.2 M sucrose, 1 mM DTT, 1 mM ATP, 5 mM creatine
phosphate, 10 U creatine kinase, 0.5 mM myristoylated Arf1, 0.5 mCi
35S-GTPgS, 10 mM GTPgS, and 2.5 mg rat liver Golgi membranes
(based on protein contents) at 37ºC for 1 hr. Rat liver Golgi mem-
branes were isolated as described in Hui et al. (1998). Where indi-
cated, 1 mM His-tagged 3A(1–60) protein was added. Protein-bound
35S-GTPgS was recovered by filtration through 0.45 mm nitrocellu-
lose filters. The total amount of radioactive label on the filters was
determined by liquid scintillation counting.
Interaction Studies
Yeast 2-hybrid studies were performed in strain AH109 (Clontech).
The Arf GEF regions and the Arf proteins were cloned into pGADT7
creating Gal4 activation domain fusions, and the first 60 amino acids
of 3A were cloned into pGBT7 to produce a Gal4 DNA binding
domain fusion protein. Coimmunoprecipitation was performed as
described for the A1PI secretion assay in Wessels et al. (2005).
GST fusion proteins were purified from E.coli. Murine brain lysates
were prepared from adult F13wt mice in RIPA buffer. Rat liver Golgi
fractions were isolated as described in Hui et al. (1998). For pull-
down experiments, 2.5 mg murine brain lysate proteins or 0.5 mg
rat liver Golgi fractions were added to GST-3A(1–60) protein in 1.5 ml
IPP150 and allowed to bind for 1 hr at 4ºC. Proteins were bound to
glutathione Sepharose for 1 hr at 4ºC, washed three times with
IPP150, and analyzed by immunoblotting. The Arf1 column binding
assay was performed as described in Trautwein et al. (2004) with
minor modifications.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and five figures and are available at http://www.developmentalcell.
com/cgi/content/full/11/2/191/DC1/.
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